Nektar Therapeutics SEC Filings

NEKTAR THERAPEUTICS (NKTR) Form 4 summary: Director Greer R. Scott received a non-derivative award in the form of a stock option grant on 09/30/2025 for 8,000 options with a stated conversion/exercise price of $56.90. The reported option is exercisable beginning 09/29/2033 and the filing shows 8,000 shares benefically owned following the transaction, held directly. The filing notes the option vests in substantially equal monthly installments over the one-year period beginning on 09/30/2025. The form was signed by an attorney-in-fact on 10/01/2025. The document discloses a standard director compensation award rather than a sale or disposition.

Diana Brainard, a director of Nektar Therapeutics (NKTR), was granted an option for 8,000 shares on 09/30/2025. The option has an exercise price of $56.90 and is recorded as a direct holding of 8,000 underlying shares following the transaction. The option vests in substantially equal monthly installments over the one-year period beginning on September 30, 2025, and the instrument shows an exercisable/expiration date of 09/29/2033. The Form 4 is signed by an attorney-in-fact on 10/01/2025, reporting the acquisition (code A) of the derivative security.

Jeffrey Robert Ajer, a director of Nektar Therapeutics (NKTR), acquired a derivative grant of 8,000 stock options on 09/30/2025. The options have a stated conversion/exercise price of $56.9 and the filing reports 8,000 underlying shares of common stock. The filing notes the options vest in substantially equal monthly installments over the one-year period beginning on September 30, 2025. The form indicates an expiration/related date of 09/29/2033 and shows the shares are beneficially owned directly following the transaction. The Form 4 was signed by an attorney-in-fact on 10/01/2025.

Insider sales by Nektar Therapeutics CEO and Director Robin W. Howard are reported on Form 4. On 09/09/2025 Mr. Howard sold a series of common stock lots under a disclosed Rule 10b5-1 trading plan: 2,100 shares at a weighted average price of $45.16, 1,200 shares at $46.41, 2,156 shares at $47.49, and 1,210 shares at $48.18. The filings show his beneficial ownership declined through the sequence from 53,908 shares to 49,342 shares after the last reported sale; an indirect holding of 28 shares is listed as held by his spouse. The report was executed under an established trading plan and the filer states willingness to provide trade-level details on request.

Form 144 filed for NKTR (Nektar Therapeutics) reports a proposed sale of 6,666 common shares by an insider through Fidelity Brokerage Services on 09/09/2025 on NASDAQ, with an aggregate market value of $311,204.76. The filing lists total shares outstanding as 19,018,573. The shares to be sold match the sum of restricted stock vesting awards acquired between 05/15/2016 and 11/15/2021 that total 6,666 shares and were granted as compensation. The seller is identified as Howard Robin at the provided address. Recent dispositions by the same person in the prior three months total 14,905 shares for gross proceeds of $518,026.81 across four sales dated 08/19/2025 through 09/05/2025. The filing does not include the issuer name, CIK, or certain contact details in the provided text.

Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics (NKTR), reported four sales of company common stock on 09/04/2025 under a Rule 10b5-1 trading plan. The transactions disposed of 1,721 shares in total (793; 432; 189; 307) at weighted average prices of $32.43, $33.60, $34.41, and $35.69 respectively, with execution price ranges disclosed for each lot. Following these sales, the reporting person beneficially owned 17,462 shares (direct ownership). The filing indicates the trades were executed pursuant to a pre-established plan and the filer offers to provide full trade-by-trade details on request.

Robin W. Howard, President & CEO and director of Nektar Therapeutics (NKTR), sold a total of 11,832 shares of common stock under a Rule 10b5-1 trading plan on September 4-5, 2025. The sales were reported in several block transactions with weighted-average prices reported at $32.37, $33.54, $34.40, $35.80, $37.87, $38.82 and $39.89. Following these dispositions the reporting person beneficially owned 56,008 shares directly; an additional 28 shares are held indirectly by the reporting person’s spouse. The filer states the transactions were effected pursuant to a 10b5-1 plan and provides price ranges for each grouped trade.

Nektar Therapeutics (NKTR) notice reports a proposed sale of 6,666 common shares with an aggregate market value of $256,837.92, representing a portion of ~19.02 million shares outstanding. The filing identifies the broker as Fidelity Brokerage Services LLC and lists the approximate date of sale as 09/05/2025 on NASDAQ. The 6,666 shares to be sold were acquired through restricted stock vesting between 05/15/2017 and 05/15/2021 as compensation from the issuer, and the acquisition table shows the same 6,666-share total when summed. The filer also disclosed three sales in the prior three months totaling 8,239 shares for gross proceeds of $261,188.89. The notice includes the seller's attestation regarding absence of undisclosed material adverse information.